中图分类号R956 文献标志码A 文章编号 1001-0408(2025)08-0945-06

    DOI 10.6039/j.issn.1001-0408.2025.08.09

    Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-smallcellung cancer WANG Hong'， LI Haonan2'3， ZHANG ， LIU Yuhang'4， XU Yeyoul.4， WENG Kaiyuan' (1. School of Medical Business， Guangdong Pharmaceutical University， Guangdong 510o6， China； 2. School of Pharmaceutical Sciences， Peking University， Beijing 100l9l， China； 3. International Research Center for Medicinal Administration， Peking University， Beijing 10o191， China； 4. Health Economics and Promotion Research Center， Guangdong Pharmaceutical University， Guangzhou 510o06， China)

    ABSTRACTOBJECTIVETo evaluatethecost-efectivenessofiruplinalkibfor ALK-positienon-smallcell lung cancer (NSCLC)patientswhohadnot previouslyreceivedALK-tyrosine kinase inhibitors(TKIs)fromtheperspectiveof the Chinese healthcaresystem.METHODSBasedontheINSPIREclinicaltrialathreeealthstatepartitionedsurvivalmodelwasdeveloped to simulatetheprogressionofdisease ......